Stent Thrombosis in the Era of the Drug-Eluting Stent.
10.4070/kcj.2005.35.11.791
- Author:
Duk Woo PARK
1
;
Seong Wook PARK
Author Information
1. Department of Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea. swpark@amc.seoul.kr
- Publication Type:Review ; Clinical Trial
- Keywords:
Thrombosis;
Drug-eluting stent
- MeSH:
Drug-Eluting Stents*;
Stents*;
Thrombosis*
- From:Korean Circulation Journal
2005;35(11):791-794
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Coronary stent thrombosis (ST) has been regarded as a rare but catastrophic complication of bare-metal stent (BMS) implantation that normally occurs during the first few weeks after stenting. In the drug-eluting stent (DES) era, there has been increasing concern regarding higher rates of ST due to delayed endothelialization. However, a pooled meta-analysis of randomized clinical trials and registry studies showed rates of ST (0.4-1.5%) after DES to be similar to those of BMS. The rate of ST did not differ between sirolimus- and paclitaxel-eluting stents. Additionally, the rates of late ST were similar between DES and BMS. Remarkably, very late occurrence of ST, which develops up to 1-2 years after DES implantation, was significantly associated with complete cessation of antiplatelet therapy. Further large-scale studies are needed to determine the optimal combination and duration for antiplatelet therapy in order to prevent these serious thrombotic events.
